Apellis Pharmaceuticals, Inc. (APLS)

25.15 +0.33 (+1.33%) USD  |  NASDAQ  |  Dec 24, 12:59
25.16 0.00 (0.00%) After-Hours: 13:51
More

Apellis Pharmaceuticals SG&A Expense (TTM): 524.64M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for APLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Biogen, Inc. 2.431B
Amicus Therapeutics, Inc. 353.07M
Fortress Biotech, Inc. 108.70M
Ultragenyx Pharmaceutical, Inc. 343.56M
Fulcrum Therapeutics, Inc. 29.10M